ELTX ANGION BIOMEDICA CORP

Elicio Therapeutics to Present at the B. Riley Securities 4th Annual Oncology Conference

Elicio Therapeutics to Present at the B. Riley Securities 4th Annual Oncology Conference

BOSTON, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that Robert Connelly, Chief Executive Officer, and Christopher Haqq, M.D., Ph.D., Executive Vice President, Head of Research and Development, and Chief Medical Officer will participate in a fireside chat at the B. Riley Securities 4th Annual Oncology Conference on January 18, 2024 at 2:30 PM ET.

To access this event, please RSVP to your B. Riley Securities sales representative. A replay of Elicio’s fireside chat will be accessible under “” in the Investors section of Elicio’s website, , after the meeting.

About Elicio Therapeutics

Elicio Therapeutics is a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer. By combining expertise in immunology and immunotherapy, Elicio is engineering investigational Amphiphile (“AMP”) immunotherapies intended to precisely target and fully engage the lymph nodes, the site in our bodies where the immune response is orchestrated. Elicio is engineering lymph node-targeted AMPlifiers, immunomodulators, adjuvants and vaccines for an array of aggressive cancers.

Media Contact

Kristin Politi

LifeSci Communications



646-876-4783

Investor Relations Contact

Heather DiVecchia

Elicio Therapeutics



857-209-0153



EN
16/01/2024

Underlying

ELTXANGION BIOMEDICA CORP

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ANGION BIOMEDICA CORP

 PRESS RELEASE
Free
ELTX ANGION BIOMEDIC...

Elicio Therapeutics to Present at the TD Cowen 46th Annual Health Care...

Elicio Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference BOSTON, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that Robert Connelly, Chief Executive Officer, and Pete DeMuth, PhD, Chief Scientific Officer, will participate in the upcoming TD Cowen 46th Annual Health Care Conference, taking place March 2-4, 2026, in Boston, MA. TD Cowen 46th Annual Health Care ConferenceFormat: ...

February 25, 2026 1 EN
 PRESS RELEASE
Free
ELTX ANGION BIOMEDIC...

Elicio Therapeutics Reports Inducement Grants

Elicio Therapeutics Reports Inducement Grants BOSTON, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that on February 17, 2026, Elicio granted an aggregate of 30,300 inducement stock options to a new employee, as an inducement material to such individual entering into employment with Elicio in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement stock options were approved by the Compensation Co...

February 18, 2026 1 EN
 PRESS RELEASE
Free
ELTX ANGION BIOMEDIC...

Elicio Therapeutics Reports Inducement Grants

Elicio Therapeutics Reports Inducement Grants BOSTON, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that on January 15, 2026, Elicio granted an aggregate of 22,400 inducement stock options to two new employees, as an inducement material to each individual entering into employment with Elicio in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement stock options were approved by the Compensation ...

January 16, 2026 1 EN
 PRESS RELEASE
Free
ELTX ANGION BIOMEDIC...

Elicio Therapeutics Reports Inducement Grants

Elicio Therapeutics Reports Inducement Grants BOSTON, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that on December 15, 2025, Elicio granted an aggregate of 157,193 inducement stock options to three new employees, as an inducement material to each individual entering into employment with Elicio in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement stock options were approved by the Compensat...

December 16, 2025 1 EN
 PRESS RELEASE
Free
ELTX ANGION BIOMEDIC...

Elicio Therapeutics Reports Antigen Spreading to Patient-Specific Neoa...

Elicio Therapeutics Reports Antigen Spreading to Patient-Specific Neoantigens Beyond mKRAS in Ongoing Phase 2 AMPLIFY-7P Trial Antigen spreading was evaluated in a subset of Phase 2 patients to assess the ability of ELI-002 7P to broaden immune responses to personalized tumor neoantigens not present in the targeted immunotherapy87% (13/15) of evaluated patients demonstrated induction of T cell responses to tumor neoantigens beyond mKRAS following ELI-002 7P therapyThe induction of non-mKRAS antigen-specific T cell responses supports the potential for ELI-002 7P to generate a broader, more a...

December 11, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch